Description
Created On: 2020-07-15
Record Count: 4
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Pain
- Gastrointestinal
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3196
The Licensor granted License of relevant know-how, patent rights and technology,for Relistor® (methylnaltrexone bromide) subcutaneous injection, to the Licensee, a leading gastrointestinal disease specialty company.
OIC is the constipation that often arises when patients take opioids for pain relief.
IPSCIO Record ID: 2796
IPSCIO Record ID: 26353
IPSCIO Record ID: 279342
Combination Product means any Product that contains the Compound as an active ingredient together with one or more other active ingredients and is sold for a single invoiced price, e.g., where the Compound is packaged for sale together with a second compound or biologic as an active ingredient (either as a single fixed dose or as separate doses).
Compound means R-methyinaltrexoun (R-MNTX) which is chemically defined as morphinanium, 17R, 17-(cyclopropylmethyl)-4, 5-epoxy-3,14-dihydroxy-17-methyl-6-oxo-, bromide, (5a)-(9C1), and its pharmacologically acceptable salts, together with their solvates, hydrates, hemihydrates, metabolites, pro-drugs, esters, and if applicable, any isomers or racemates thereof, but excluding any of the foregoing olecules whose primary mechanism of action is as an opioid agonist. The “Compound†does not include the Excluded Molecules.
Licensor Patent Rights means any Patent Right Controlled by Licensor or its Affiliates as of the Effective Date or at any time during the Term that relates to, claims, or if issued, would be infringed by an unlicensed Third Party’s manufacture, use, sale, importation, Development or Commercialization of the Compound, or any Product; provided, however, that if a Third Party becomes an Affiliate of Licensor pursuant to a transaction or series of related transactions as a result of which such Third Party is able to elect a majority of the members of the board of directors of Licensor (or its successor company) or any of its “controlling Affiliates†(as defined in this agreement) (Licensor Change of Control), “Licensor Patent Rights†will not include any Patent Rights that were Controlled by such Third Party prior to the completion of such transaction or series of related transactions. Licensor Patent Rights are identified as:
4,719,215 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
4,861,781 – Quaternary derivatives of noroxymorphone which relieve nausea and emesis
5,102,887 – Method for reducing emesis and nausea induced by the administration of an emesis causing agent
Joint Patent Rights means any Patent Rights related to any invention, development or discovery made or created in the course of the Collaboration jointly by (i) employees or agents of Licensor or any of its Affiliates, and (ii) employees or agents of Licensee or any of its Affiliates, as determined in accordance with this agreement (Inventorship).
Licensor Technology means the Licensor Know-How and the Licensor Patent Rights.
Joint Technology means the Joint Know-How and the Joint Patent Rights.
To relieve pain, narcotic medications such as morphine activate specific opioid receptors located in the central nervous system – the brain and spinal cord. Opioids, however, also interact with these receptors outside of the central nervous system, resulting in side effects, which can be debilitating, including constipation, urinary retention and severe itching. MNTX is designed to block peripheral opioid receptors whose activation causes these side effects. As MNTX does not cross the blood-brain barrier, it does not interfere with brain-centered pain relief.